Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.60
−$0.41 · -4.55%
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Previous close
$8.60
−$0.41 · -4.55%
Regular session · ET · Market data may be delayed.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Day range
Current $8.60
52-week range
Current $8.60
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
39
Expensive
Sentiment
62
Bullish
Risk
66
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Day range
Current $8.60
52-week range
Current $8.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 13.19M USD | — | 4.49M USD | 4.85M USD | 1.47M USD |
| Cost of goods sold | 62.68K USD | — | 97.64K USD | 418.47K USD | 217.53K USD |
| Gross profit | 13.12M USD | — | 4.39M USD | 4.44M USD | 1.25M USD |
| Research and development | 12.37M USD | 14.9M USD | 22.4M USD | 22.63M USD | 21.33M USD |
| Selling, general, and administrative | 9.48M USD | 7.81M USD | 12.27M USD | 15.29M USD | 16.51M USD |
| Operating expenses | 21.85M USD | 17.46M USD | 26.89M USD | 36.89M USD | 37.84M USD |
| Interest income | 297.12K USD | — | — | — | — |
| Interest expense | 6.73K USD | 15.03K USD | 17.11K USD | 20.01K USD | 29.68K USD |
| Depreciation and amortization | 62.68K USD | 258.92K USD | 339.08K USD | 288.33K USD | 126.67K USD |
| Operating income | −8.67M USD | −17.46M USD | −22.5M USD | −32.46M USD | −36.59M USD |
| Net income | −8.38M USD | −17.31M USD | −29.74M USD | −24.04M USD | −36.2M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$47.50
452.33% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 12, 2025 | 1:50 | — | — |
Stock split | Aug 31, 2022 | 1:25 | — | — |
Stock split | Sep 27, 2010 | 1:10 | — | — |
Stock split | Sep 8, 1997 | 1:4 | — | — |
Stock split | Jul 22, 1996 | 1:10 | — | — |
Effective Aug 12, 2025
1:50
Effective Aug 31, 2022
1:25
Effective Sep 27, 2010
1:10
Effective Sep 8, 1997
1:4
Effective Jul 22, 1996
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
